Anthracycline Market Rising Trends, Key Leading Players, Trends Analysis, Industry Share And Forecast To 2033

The new report published by The Business Research Company, titled Anthracycline Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the anthracycline market size has grown strongly in recent years. It will grow from $1.41 billion in 2023 to $1.52 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The anthracycline market size is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12914&type=smp

Rising Cancer Prevalence Fuels Growth In The Anthracycline Market
The increasing prevalence of cancer is expected to propel the growth of the anthracycline market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries and either spread to other organs or invade neighboring body parts. Anthracycline, a class of chemotherapy drugs, plays a significant role in cancer treatment as it prevents cell division by disrupting the structure of the DNA and terminating its function. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, 1.9 million new cancer cases are expected to be diagnosed in the US, an increase from 1.8 million new cancer cases diagnosed in 2020. Further, around 609,820 cancer-related deaths are anticipated in 2023, with an expected 606,520 in 2020. Therefore, the increasing prevalence of cancer is driving the growth of the anthracycline market.

Innovative Approaches And Generic Offerings Shape The Anthracycline Production
Major companies operating in the anthracycline market are focused on developing innovative novel drugs such as Doxorubicin Liposome Injection to sustain their position in the market. For instance, in October 2021, Padagis LLC, an Israel-based pharmaceutical company that produces generic prescription medicines, announced the FDA's (Food and Drug Administration) approval and launch of a generic version of Doxil (Doxorubicin Liposome Injection) with an AB rating. The company has launched the drug through a partnership with Ayana Pharma Ltd., an Israel-based developer of liposomal drugs for cancer therapeutics. Doxil liposome injection is an anthracycline topoisomerase inhibitor used to treat ovarian cancer, Kaposi's sarcoma related to AIDS (acquired immunodeficiency syndrome) and multiple myeloma. This treatment functions by inhibiting or decelerating the proliferation of cancerous cells. It is introduced into a vein through an injection lasting 30-60 minutes or more.

The anthracycline market covered in this report is segmented -

1) By Drugs: Daunorubicin; Doxorubicin; Epirubicin; Idarubicin; Mitoxantrone; Valrubicin
2) By Dosage: Powder; Capsule; Solution; Injection; Suspension; Other Dosages
3) By Application: Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Bladder Cancer; Breast Cancer; Other Metastatic Cancers
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12914&type=discount

Major players in the anthracycline market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA, Merck & Co. Inc., Gilead Sciences Inc., Zydus Lifesciences Limited, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Gland Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Accord Healthcare Limited, Athenex Inc., Miracalus Pharma Pvt. Ltd., Transo-Pharm Usa LLC, BluePoint Laboratories, Areva Pharmaceuticals Inc., GeneraMedix Inc., Salius Pharma Pvt. Ltd.

Contents of the report:
1. Executive Summary
2. Anthracycline Market Report Structure
3. Anthracycline Market Trends And Strategies
4. Anthracycline Market - Macro Economic Scenario
5. Anthracycline Market Size And Growth
…..
27. Anthracycline Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/anthracycline-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.